Cytox has developed a genetic test, genoSCORE for assessing the risk of cognitive decline associated with future onset of Late-onset Alzheimer’s disease (AD).
Supported by leading academics from the Universities of Cardiff, Exeter and UCL, Cytox has created a DNA-profiling array which is interpreted using a polygenic risk score (PRS) algorithm to determine the likelihood of developing AD. The development of new AD drugs suffers from a >99% failure rate. Due to the lack of an effective early diagnostic test, costly PET scans are used to identify AD patients, resulting in extremely high clinical trial recruitment costs.
Richard has been involved in the development of diagnostic and therapeutic pharmaceutical products for more than 20 years. He has held senior R&D and leadership positions in global pharmaceutical companies including GE Healthcare (Medical Diagnostics), UCB-Celltech, Lorantis and Amersham plc. During this time, he was involved in the development of a novel 18F-PET radiopharmaceutical for imaging amyloid deposition in the brains of Alzheimer’s disease patients.